期刊
JOURNAL OF NEUROLOGY
卷 268, 期 7, 页码 2379-2389出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-019-09690-6
关键词
Disease-modifying therapy (DMT); Multiple sclerosis (MS); Lymphopenia
资金
- Projekt DEAL
This review summarizes the predicted and unintended adverse effects of disease-modifying therapies for multiple sclerosis on leukocytes in peripheral blood, highlighting the importance of vigilance for potential therapeutic risks when prescribing medications.
Modern disease-modifying therapies (DMTs) in multiple sclerosis (MS) have variable modes of action and selectively suppress or modulate the immune system. In this review, we summarize the predicted and intended as well as unwanted adverse effects on leukocytes in peripheral blood as a result of treatment with DMTs for MS. We link changes in laboratory tests to the possible therapeutic risks that include secondary autoimmunity, infections, and impaired response to vaccinations. Profound knowledge of the intended effects on leukocyte counts, in particular lymphocytes, explained by the mode of action, and adverse effects which may require additional laboratory and clinical vigilance or even drug discontinuation, is needed when prescribing DMTs to treat patients with MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据